Brandon P. Moss

Brandon P. Moss

Neurology

2049 East 100th Street
Cleveland, OH 44106

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Neuropsychological functioning in clinically referred patients with sarcoidosis: a preliminary investigation.

Neuropsychological functioning in clinically referred patients with sarcoidosis: a preliminary investigation.

Journal: Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists

Published: January 13, 2026

Sarcoidosis of the nervous system: a rare but serious manifestation.

Sarcoidosis of the nervous system: a rare but serious manifestation.

Journal: Current opinion in immunology

Published: October 05, 2025

Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database.

Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database.

Journal: Journal of comparative effectiveness research

Published: February 12, 2025

Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice.

Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice.

Journal: Neurodegenerative disease management

Published: January 21, 2025

Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.

Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.

Journal: Neurology. Clinical practice

Published: May 14, 2024

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity.

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity.

Journal: RMD open

Published: August 05, 2022

Neurosarcoidosis: an update on diagnosis and therapy.

Neurosarcoidosis: an update on diagnosis and therapy.

Journal: Expert review of neurotherapeutics

Published: August 01, 2022

Exploring the impact of the COVID-19 pandemic on social isolation and mental health in people with MS.

Exploring the impact of the COVID-19 pandemic on social isolation and mental health in people with MS.

Journal: Multiple sclerosis and related disorders

Published: May 06, 2022

Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series.

Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series.

Journal: Journal of neuroimmunology

Published: May 02, 2022

Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis.

Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: February 22, 2022

Clinical perspective on clinical outcome assessments in neurosarcoidosis.

Clinical perspective on clinical outcome assessments in neurosarcoidosis.

Journal: Multiple sclerosis and related disorders

Published: September 28, 2021

Perspectives and experiences with COVID-19 vaccines in people with MS.

Perspectives and experiences with COVID-19 vaccines in people with MS.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: September 10, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026